Coloplast A/S Series B,

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
  • TickerCOLO B
  • ISINDK0060448595
  • ExchangeNasdaq Nordic Copenhagen
  • SectorHealth Care Equipment & Services
  • CountryDenmark

Analysts

Debbie Wang

Coloplast Remains On Track After Solid Fiscal Third-Quarter Results; No Change to Our FVE

Coloplast’s fiscal third-quarter performance reliably met our expectations, and the incremental adjustments we’ve made to our assumptions did not materially shift our fair value estimate. Thanks to a steady stream of new products, Coloplast has consistently outpaced market growth, racking up 8% organic revenue growth in the third quarter. As we had seen in the second quarter, the U.S. market continues to look like a soft spot for Coloplast, as McKesson has been consolidating 15 of its warehouses...

Debbie Wang

No Surprises in Coloplast's Fourth Quarter; Our Fair Value Estimate Remains the Same

Coloplast’s fiscal fourth-quarter results largely fell in line with our expectations and we're leaving our fair value estimate unchanged for now. Shares seem to have drifted lower as some investors have questioned whether Coloplast can continue to improve operating margin at the pace it has over the 2009-13 period, especially considering that profitability has generally plateaued over the past two years. Over the summer, management had indicated the wide-moat firm could raise operating profit 50...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Debbie Wang

Coloplast's ability to innovate keeps the firm in a leadership position.

Coloplast’s fiscal fourth-quarter results largely fell in line with our expectations and we're leaving our fair value estimate unchanged for now. Shares seem to have drifted lower as some investors have questioned whether Coloplast can continue to improve operating margin at the pace it has over the 2009-13 period, especially considering that profitability has generally plateaued over the past two years. Over the summer, management had indicated the wide-moat firm could raise operating profit 50...

Debbie Wang

Coloplast Delivers Strong First-Quarter Results; No Change to Our Fair Value Estimate

Coloplast’s first-quarter results closely matched our expectations, and we’re leaving our fair value estimate unchanged. We were pleased to see strength in the ostomy and urology segments again this quarter, with growth of 6% and 8%, respectively, in constant currency. Despite foreign currency headwinds, underlying demand in Europe remained robust, and the firm continues to make progress in recovering from earlier stumbles in the British market. We saw little in the quarter to change our thinkin...

Debbie Wang

Coloplast Remains On Track After Solid Fiscal Third-Quarter Results; No Change to Our FVE

Coloplast’s fiscal third-quarter performance reliably met our expectations, and the incremental adjustments we’ve made to our assumptions did not materially shift our fair value estimate. Thanks to a steady stream of new products, Coloplast has consistently outpaced market growth, racking up 8% organic revenue growth in the third quarter. As we had seen in the second quarter, the U.S. market continues to look like a soft spot for Coloplast, as McKesson has been consolidating 15 of its warehouses...

Debbie Wang

No Surprises in Coloplast's Fourth Quarter; Our Fair Value Estimate Remains the Same

Coloplast’s fiscal fourth-quarter results largely fell in line with our expectations and we're leaving our fair value estimate unchanged for now. Shares seem to have drifted lower as some investors have questioned whether Coloplast can continue to improve operating margin at the pace it has over the 2009-13 period, especially considering that profitability has generally plateaued over the past two years. Over the summer, management had indicated the wide-moat firm could raise operating profit 50...

Debbie Wang

Coloplast's ability to innovate keeps the firm in a leadership position.

Coloplast’s fiscal fourth-quarter results largely fell in line with our expectations and we're leaving our fair value estimate unchanged for now. Shares seem to have drifted lower as some investors have questioned whether Coloplast can continue to improve operating margin at the pace it has over the 2009-13 period, especially considering that profitability has generally plateaued over the past two years. Over the summer, management had indicated the wide-moat firm could raise operating profit 50...

Debbie Wang

Coloplast Delivers Strong First-Quarter Results; No Change to Our Fair Value Estimate

Coloplast’s first-quarter results closely matched our expectations, and we’re leaving our fair value estimate unchanged. We were pleased to see strength in the ostomy and urology segments again this quarter, with growth of 6% and 8%, respectively, in constant currency. Despite foreign currency headwinds, underlying demand in Europe remained robust, and the firm continues to make progress in recovering from earlier stumbles in the British market. We saw little in the quarter to change our thinkin...

Debbie Wang

Coloplast Delivers Solid Second-Quarter Results; Our Fair Value Estimate Remains Unchanged

Coloplast posted solid second-quarter results that are generally consistent with our projections, and we’re holding steady on our fair value estimate. The firm delivered quarterly organic growth of 7%, fueled primarily by continued strength in its ostomy and continence care product lines, which together account for roughly 75% of total revenue. Coloplast kept a tight hold on expenses, and the firm remains on track to meet our full-year estimates. We see little in the quarter to shift our view of...

1 director bought

A director at Coloplast As bought 36,500 shares at 765.701DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Antti Kansanen ...
  • Christer Magnergård
  • Eivind Sars Veddeng
  • Håkon Astrup
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mattias Holmberg
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Weak H1, risky 2018 but interesting 2019e

Antti Kansanen ...
  • Håkon Astrup
  • Helge André Martinsen
  • Mattias Holmberg
  • Niclas Gehin
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Eivind Sars Veddeng ...
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Mattias Holmberg
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Mattias Holmberg ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Nurhayati Wan

Coloplast

null

Nurhayati Wan

Coloplast

null

Nurhayati Wan

Coloplast

null

Nurhayati Wan

Coloplast

null

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.Under ITEM...

Expert Corporate Governance Service (ECGS)

Coloplast - 2018, December 5th

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. On November 1, 2018, the Company announced that Mr. L.S. Rasmussen will resign from his position as CEO to become the new Chairman of the board of directors as of this AGM. Mr. Rasmussen will be succeeded by Executive Vice President - Mr. Kristian Villumsen - as of the same date.   Under ITEM 5.1, it is proposed to re-appoint Mr. N.P. Louis Hansen as Vice Chairman of the board of directors. Although ECGS has no (major) concerns over the re-appointment...

Coloplast – Proxinvest Corporate Governance Rating ® : E

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch